Greenwich Lifesciences Inc (GLSI) FinancialsGLSIGreenwich Lifesciences Inc

Evaluating the bottom line, Greenwich Lifesciences Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -986.32%, provide a clear picture of how effectively GLSI converts its operational activities into shareholder value.

In the context of the broader market, GLSI competes directly with industry leaders such as CABA and LRMR. With a market capitalization of $240.02M, it holds a significant position in the sector. When comparing efficiency, GLSI's gross margin of N/A stands against CABA's N/A and LRMR's N/A. Such benchmarking helps identify whether Greenwich Lifesciences Inc is trading at a premium or discount relative to its financial performance.

The company has shown a significant increase in its stock price over the past year, with a 103.46% increase, but continues to report negative net income, indicating ongoing financial challenges.